CN101229334A - 治疗风湿性、类风湿性关节炎的药物 - Google Patents
治疗风湿性、类风湿性关节炎的药物 Download PDFInfo
- Publication number
- CN101229334A CN101229334A CNA2008100453010A CN200810045301A CN101229334A CN 101229334 A CN101229334 A CN 101229334A CN A2008100453010 A CNA2008100453010 A CN A2008100453010A CN 200810045301 A CN200810045301 A CN 200810045301A CN 101229334 A CN101229334 A CN 101229334A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- active drug
- rheumatoid arthritis
- medicinal raw
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 165
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 21
- 229940079593 drug Drugs 0.000 title claims description 96
- 206010003246 arthritis Diseases 0.000 title description 2
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 241000903946 Clematidis Species 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 43
- 239000000284 extract Substances 0.000 claims description 41
- 210000000582 semen Anatomy 0.000 claims description 40
- 239000000341 volatile oil Substances 0.000 claims description 25
- 208000025747 Rheumatic disease Diseases 0.000 claims description 14
- 230000000552 rheumatic effect Effects 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 11
- 241000756943 Codonopsis Species 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 12
- 239000004615 ingredient Substances 0.000 abstract description 6
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000758794 Asarum Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 67
- 238000012360 testing method Methods 0.000 description 50
- 241000700159 Rattus Species 0.000 description 39
- 230000000694 effects Effects 0.000 description 21
- 239000012153 distilled water Substances 0.000 description 20
- 230000008961 swelling Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 16
- 238000001035 drying Methods 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 238000010171 animal model Methods 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 208000009386 Experimental Arthritis Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 230000000202 analgesic effect Effects 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 238000004821 distillation Methods 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 210000001835 viscera Anatomy 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 229920001353 Dextrin Polymers 0.000 description 7
- 239000004375 Dextrin Substances 0.000 description 7
- 208000004044 Hypesthesia Diseases 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 230000036592 analgesia Effects 0.000 description 7
- 235000019425 dextrin Nutrition 0.000 description 7
- 208000034783 hypoesthesia Diseases 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 231100000862 numbness Toxicity 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 240000001624 Espostoa lanata Species 0.000 description 6
- 235000009161 Espostoa lanata Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 238000005498 polishing Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- -1 Resina persicae Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001550206 Colla Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000157049 Microtus richardsoni Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000005498 Setaria italica Species 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000002252 panizo Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
滑膜病变 | 关节软骨损伤 | 骨髓炎 | ||||
增厚程度 | 充血水肿 | 炎细胞浸润 | ||||
正常组 | - | - | - | - | - | |
蒸馏水组 | ++ | +++ | ++ | - | - | |
对照药物组 | + | ++ | + | - | - | |
本发明药物 | 大剂量 | + | +~++ | + | - | - |
中剂量 | + | +~++ | + | - | - | |
小剂量 | + | +~++ | + | - | - |
动物数(只) | 剂量(g/kg) | 肿胀度(mg) | ||
蒸馏水空白组 | 10 | 等容量 | 12.71±3.60 | |
对照药物组 | 10 | 3.6 | 8.90±3.86* | |
本发明药物组 | 小剂量 | 10 | 0.70 | 8.86±3.54* |
中剂量 | 10 | 1.40 | 11.15±3.88 | |
大剂量 | 10 | 2.97 | 8.24±5.30 |
肿胀度 | |||||
1小时 | 2小时 | 3小时 | 4小时 | ||
蒸馏水组 | 1.00±0.19 | 0.91±0.26 | 0.97±0.24 | 0.79±0.22 | |
对照药物组 | 1.02±0.21 | 0.77±0.21 | 0.81±0.24 | 0.71±0.18 | |
本发明药物组 | 小剂量 | 0.62±032 | 0.65±0.27* | 0.52±0.30** | 0.48±0.18** |
中剂量 | 0.80±0.35 | 0.69±0.32 | 0.71±0.31 | 0.62±0..5 | |
大剂量 | 0.82±0.18 | 0.69±0.24* | 0.65±0.22** | 0.53±0.27* |
肉芽重(g) | |||
湿重 | 干重 | ||
蒸馏水空白组 | 0.5979±0.0425 | 0.1396±0.0330 | |
对照药物组 | 0.5646±0.0479 | 0.0907±0.0117** | |
本发明药物组 | 小剂量 | 0.5105±0.1162 | 0.0909±0.0314** |
中剂量 | 0.5776±0.0707 | 0.0948±0.0097 | |
大剂量 | 0.5218±0.0939* | 0.0875±0.0717** |
0.5小时 | 1小时 | 2小时 | 4小时 | ||||||
痛阈值(s) | 镇痛率(%) | 痛阈值(s) | 镇痛率(%) | 痛阈值(s) | 镇痛率(%) | 痛阈值(s) | 镇痛率(%) | ||
蒸馏水组 | 20.3±4.14 | - | 22.5±4.30 | - | 22.7±2.91 | - | 23.7±3.74 | - | |
对照药物组 | 22.2±6.80 | 9.35 | 23.8±5.84 | 5.78 | 25.6±12.26 | 12.78 | 29.3±13.23 | 23.63 | |
本发明药物组 | 小剂量 | 30.3±10.85 | 49.26 | 37.5±10.79 | 66.67 | 35.1±13.09 | 54.63 | 40.7±11.75 | 71.73 |
中剂量 | 26.6±9.59 | 31.03 | 27.9±8.86 | 24.00 | 53.0±8.20 | 133.48 | 55.5±6.38 | 134.18 | |
大剂量 | 27.6±8.33 | 35.96 | 39.8±16.25 | 76.89 | 54.9±10.82 | 141.85 | 58.7±2.06 | 147.68 |
潜伏期(s) | 10分钟 | 20分钟 | ||||
扭体次数 | 抑制率(%) | 扭体次数 | 抑制率(%) | |||
蒸馏水组 | 89.5±34.68 | 20.6±5.12 | - | 35.8±6.88 | - | |
对照药物组 | 179.1±58.26 | 10.9±4.46 | 47.08 | 17.9±4.75 | 50.00 | |
本发明药物组 | 小剂量 | 166.6±57.51 | 8.9±3.84 | 56.80 | 15.8±4.85 | 55.86 |
中剂量 | 177.9±52.35 | 10.6±3.40 | 50.00 | 17.0±5.23 | 52.51 | |
大剂量 | 171.1±58.51 | 8.6±2.76 | 58.25 | 16.9±4.77 | 52.79 |
正常体温(℃) | 致热体温(℃) | 药后体温(℃) | |||||||
0.5小时 | 1小时 | 2小时 | 3小时 | 4小时 | 5小时 | ||||
蒸馏水组 | 37.44±0.34 | 38.94±0.38 | 38.78±0.49 | 38.57±0.45 | 38.34±0.37 | 38.10±0.43 | 38.03±0.39 | 37.95±0.36 | |
对照药物 | 37.39±0.21 | 38.85±0.38 | 38.61±0.86 | 38.12±0.69 | 37.76±0.63 | 37.60±0.63 | 37.47±0.66 | 37.40±0.55 | |
本发明药物组 | 小剂量 | 37.43±0.31 | 38.96±0.52 | 38.33±0.55 | 38.38±0.54 | 38.20±0.53 | 38.23±0.37 | 38.02±0.12 | 37.73±0.35 |
中剂量 | 37.44±0.30 | 38.82±0.36 | 38.29±0.27 | 37.95±0.33 | 37.83±0.36 | 37.80±0.39 | 37.66±0.80 | 37.18±0.78 | |
大剂量 | 37.45±0.30 | 38.83±0.39 | 38.26±0.28 | 37.47±0.39 | 37.42±0.31 | 37.44±0.32 | 37.55±0.30 | 37.16±0.25 |
耳肿胀度(mg) | 抑制率(%) | ||
蒸馏水空白组 | 0.90±0.30 | - | |
对照药物组 | 0.53±0.19 | 41.11 | |
本发明药物组 | 小剂量 | 0.42±0.23 | 53.33 |
中剂量 | 0.60±0.57 | 33.33 | |
大剂量 | 0.45±0.23 | 50.00 |
例数 | 显效 | 进步 | 有效 | 无效 | 总有效% | |||||
例数 | % | 例数 | % | 例数 | % | 例数 | % | |||
本发明药物 | 120 | 10 | 8.3 | 46 | 38.3 | 46 | 38.3 | 18 | 15.0 | 84.9 |
对照药物 | 119 | 8 | 6.7 | 33 | 27.7 | 51 | 42.9 | 27 | 22.7 | 77.3 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100453010A CN101229334B (zh) | 2008-01-29 | 2008-01-29 | 治疗风湿性、类风湿性关节炎的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100453010A CN101229334B (zh) | 2008-01-29 | 2008-01-29 | 治疗风湿性、类风湿性关节炎的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101229334A true CN101229334A (zh) | 2008-07-30 |
CN101229334B CN101229334B (zh) | 2010-11-24 |
Family
ID=39896347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100453010A Expired - Fee Related CN101229334B (zh) | 2008-01-29 | 2008-01-29 | 治疗风湿性、类风湿性关节炎的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101229334B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104524379A (zh) * | 2015-02-02 | 2015-04-22 | 冯波 | 一种关节炎疏风健脾利湿酊剂及制备方法 |
CN105920077A (zh) * | 2016-06-15 | 2016-09-07 | 云南中医学院 | 血满草提取物的制备方法及其在类风湿性关节炎中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101085223A (zh) * | 2007-07-05 | 2007-12-12 | 于永 | 一种治疗风湿、类风湿病的药物 |
-
2008
- 2008-01-29 CN CN2008100453010A patent/CN101229334B/zh not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104524379A (zh) * | 2015-02-02 | 2015-04-22 | 冯波 | 一种关节炎疏风健脾利湿酊剂及制备方法 |
CN105920077A (zh) * | 2016-06-15 | 2016-09-07 | 云南中医学院 | 血满草提取物的制备方法及其在类风湿性关节炎中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101229334B (zh) | 2010-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101229300B (zh) | 一种治疗骨伤疾病的中药制剂 | |
CN101019984B (zh) | 一种治疗便秘的中药制剂 | |
CN101919913B (zh) | 一种具有治疗类风湿关节炎作用的组合物 | |
CN102380015B (zh) | 治疗类风湿性关节炎的药物组合物及其制备方法和用途 | |
CN104667044A (zh) | 一种治疗痹症的中药制剂及其制备方法 | |
CN101757591B (zh) | 一种治疗慢性结肠炎、直肠炎的中药组合物 | |
CN101229334B (zh) | 治疗风湿性、类风湿性关节炎的药物 | |
CN100431593C (zh) | 一种治疗脑积水的中药制剂 | |
CN101485835B (zh) | 一种治疗骨关节炎的药物组合物及制备方法和检测方法 | |
CN104524247B (zh) | 一种治疗偏头痛的药物组合物及其用途 | |
CN102145127A (zh) | 一种治疗类风湿关节炎的药物及其制备方法 | |
CN102133273A (zh) | 一种中药降脂通便胶囊及其制备方法 | |
CN101897933A (zh) | 一种治疗白癜风的中成药 | |
CN101549025B (zh) | 一种治疗癌症的中药 | |
CN101396435B (zh) | 一种治疗胃病的中药及其制备方法和应用 | |
CN100431592C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN102488781A (zh) | 一种治疗风湿寒性关节痛的中药组合物 | |
CN101816747B (zh) | 一种防治失眠等精神疾病的药物制剂及其制备方法 | |
CN101590208B (zh) | 一种治疗类风湿关节炎的药物组合物及其制备方法 | |
CN100367997C (zh) | 一种治疗痛风病的药物及其制备方法 | |
CN101264270A (zh) | 一种治疗子宫内膜异位症的中药组合物及其制备方法 | |
CN100450537C (zh) | 一种治疗前列腺增生的中药制剂 | |
CN101024029B (zh) | 一种治疗骨性关节炎、风湿性关节炎的药物 | |
CN100408055C (zh) | 一种治疗伤科疾病的中药组合物及其制备方法和质量控制方法 | |
CN103191243A (zh) | 由黄连、吴茱萸组成的药物组合物的用途及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TIBET ZHIZHI PHARMACY GROUP CO., LTD. Free format text: FORMER OWNER: CHENGDU GIGI PHARMACEUTICAL CO., LTD Effective date: 20120322 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610072 CHENGDU, SICHUAN PROVINCE TO: 850000 LHASA, TIBET AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120322 Address after: 850000 Lhasa, Tibet autonomous region, No. 54, No. Patentee after: TIBET ZHIZHI PHARMACEUTICAL CO.,LTD. Address before: 610072, Sichuan, Chengdu, Qingjiang intersection, Vancouver square, 32 floor Patentee before: Chengdu Zhizhi Pharmaceutical Co.,Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170224 Address after: 611430 Sichuan city of Chengdu province Xinjin chuanzhe cooperation Industrial Park hope road Chengdu Zhizhi Pharmaceutical Co Ltd Patentee after: Chengdu Zhizhi Pharmaceutical Co.,Ltd. Address before: 850000 Lhasa, Tibet autonomous region, No. 54, No. Patentee before: TIBET ZHIZHI PHARMACEUTICAL CO.,LTD. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 |
|
CF01 | Termination of patent right due to non-payment of annual fee |